Abbott and Abbott Fund launch 'Future Well Kids' program to help students shape healthier lives

AbbottAbbott and its foundation, the Abbott Fund, launched Future Well™ Kids, a program designed to educate and inspire middle school students ages 10-13 to learn about the causes of chronic disease and adopt healthy habits to live healthier, fuller lives.

Chronic diseases, also known as noncommunicable diseases (NCDs) such as diabetes and cardiovascular disease, are the leading cause of death around the world. According to the World Health Organization (WHO), NCDs are estimated to account for 71% of all deaths globally and 88% of all deaths in the U.S. The conditions and behaviors that lead to NCDs often start in childhood - globally, 81% of adolescents don't get enough physical activity, and in the U.S., 32% of children and adolescents are overweight or obese.

Through Future Well Kids, Abbott employee volunteers bring their health expertise to the classroom, working with teachers in local communities. The Abbott Fund partnered with Discovery Education, the global leader in standards-aligned digital curriculum resources, engaging content and professional learning for K-12 classrooms, to develop a fun and compelling curriculum.

"Middle school is a critical time, as students are becoming more independent and making their own choices about food and physical activity," said Molly Schaefer, principal at Thomas Jefferson Middle School in Waukegan, Ill., which is participating in the Future Well Kids program. "The Future Well Kids program brings forward practical, hands-on ideas that students can use to begin establishing good habits and patterns now, which will set themselves up for a happy, healthy future."

Through classroom activities and digital lessons, students learn about good nutrition and physical fitness, and why these behaviors are so important to their health and wellbeing. And because developing healthy habits requires action, the program focuses on empowering students to take charge of their health by making simple changes in their own lives - such as creating nutritious meal plans, setting fitness goals, and learning how to differentiate between sound nutrition advice and online health fads.

"We created the Future Well Kids program to educate and empower students to develop healthy habits today, so they can reduce their risk of developing chronic diseases such as Type 2 diabetes and heart disease during their lifetime," said Jenna Daugherty, divisional vice president of global citizenship and sustainability at Abbott, and vice president of the Abbott Fund. "It's also a great way for Abbott employees to share their expertise and passion for health, working side-by-side with their neighbors to have a meaningful impact in local communities."

The Future Well Kids program serves schools that are in underserved communities near Abbott sites in California, Florida, Illinois, Michigan, Minnesota, Ohio, Texas and Virginia, as well as Ireland and Mexico. The program builds on Abbott's extensive expertise in nutrition, cardiovascular disease and diabetes care, and is designed to empower kids, support teachers and engage Abbott employees.

About Future Well

Chronic diseases - also called noncommunicable diseases, or NCDs, such as diabetes and cardiovascular disease - are among the greatest health threats of our time. These complex health challenges affect every family and every community. That's why we're working to find new answers, through our life-changing technologies, across our businesses and in partnership with others through Future Well initiatives.

Working in close collaboration with leading organizations and communities, Abbott and the Abbott Fund's Future Well initiatives are focused on finding new ways to outsmart the drivers of chronic diseases. From school-based outreach to help young people make healthier choices, to partnerships that empower communities to address social and economic barriers to good health, Future Well programs are testing new ideas to help build a healthier future.

About Abbott and the Abbott Fund

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 103,000 colleagues serve people in more than 160 countries.

The Abbott Fund is a philanthropic foundation established by Abbott in 1951. The Abbott Fund's mission is to create healthier global communities by investing in creative ideas that promote science, expand access to healthcare and strengthen communities worldwide.

Most Popular Now

Scientists uncover SARS-CoV-2-specific T cell immu…

The study by scientists from Duke-NUS Medical School, in close collaboration with the National University of Singapore (NUS) Yong Loo Lin School of Medicine, Singapore Ge...

Researchers call for worldwide biosurveillance net…

The emergence of COVID-19 is a powerful reminder of how unchecked wildlife trade can lead to the spillover spread of viruses between wildlife and humans. Understanding th...

Common FDA-approved drug may effectively neutraliz…

A common drug, already approved by the Food and Drug Administration (FDA), may also be a powerful tool in fighting COVID-19, according to research published this week in ...

New study supports remdesivir as COVID-19 treatmen…

The news about remdesivir, the investigational anti-viral drug that has shown early promise in the fight against COVID-19, keeps getting better. This week researchers at ...

Drug linked to 45% lower risk of dying among COVID…

Critically ill COVID-19 patients who received a single dose of a drug that calms an overreacting immune system were 45% less likely to die overall, and more likely to be ...

Neutralizing antibodies in the battle against COVI…

An important line of defence in the fight against the new corona virus SARS-CoV-2 is the formation of neutralising antibodies. These can eliminate the intruders and have ...

Pfizer and BioNTech granted FDA Fast Track designa…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX, "BioNTech") announced that two of the companies' four investigational vaccine candidates from their BNT162 mRNA-bas...

Sanofi and Regeneron provide update on Kevzara® (s…

Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that the U.S. Phase 3 trial of Kevzara® (sarilumab) 400 mg in COVID-19 patients requiring mechanical v...

GSK and CureVac announce strategic mRNA technology…

GlaxoSmithKline plc (LSE/NYSE: GSK) and CureVac announced the signing of a strategic collaboration agreement for the research, development, manufacturing and commercialis...

Novartis launches first-of-its-kind not-for-profit…

Novartis announced a new initiative to help patients in low-income and lower-middle-income countries (LIC; LMIC) access affordable medicines to treat the major symptoms o...

COVID-19 vaccine AZD1222 showed robust immune resp…

Interim results from the ongoing Phase I/II COV001 trial, led by Oxford University, showed AZD1222 was tolerated and generated robust immune responses against the SARS-Co...

Neutralizing antibodies isolated from COVID-19 pat…

Researchers at Columbia University Irving Medical Center have isolated antibodies from several COVID-19 patients that, to date, are among the most potent in neutralizing ...